{"id":"cromoglycate","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Disease of liver","Hepatic failure","Kidney disease","Nasal polyp"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL74","moleculeType":"Small molecule","molecularWeight":"512.33"},"aliases":["NasalCrom","DNCG Iso","Lomudal"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20"},"_scrapedAt":"2026-03-28T00:45:27.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic Keratoconjunctivitis","diseaseId":"allergic-keratoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma","diseaseId":"asthma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Asthma management","diseaseId":"asthma-management","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bronchospasm Prevention","diseaseId":"bronchospasm-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Giant papillary conjunctivitis","diseaseId":"giant-papillary-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Systemic mast cell disease","diseaseId":"systemic-mast-cell-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vernal Keratitis","diseaseId":"vernal-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vernal conjunctivitis","diseaseId":"vernal-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vernal keratoconjunctivitis","diseaseId":"vernal-keratoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03794076","phase":"PHASE1, PHASE2","title":"Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia","status":"RECRUITING","sponsor":"Vishwajit Nimgaonkar, MD PhD","startDate":"2019-04-01","conditions":"Schizophrenia, Schizo Affective Disorder","enrollment":160},{"nctId":"NCT07419880","phase":"PHASE2","title":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-30","conditions":"Triple -Negative Breast Cancer","enrollment":46},{"nctId":"NCT07142291","phase":"PHASE2","title":"PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS","status":"RECRUITING","sponsor":"PhenoNet, Inc.","startDate":"2025-11-25","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":105},{"nctId":"NCT02131038","phase":"","title":"Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2009-05","conditions":"Allergic Rhinitis","enrollment":50},{"nctId":"NCT05076682","phase":"PHASE2","title":"Reverse Triple Negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-30","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT06801626","phase":"PHASE3","title":"Novel Strategies for Reducing Burn Scar Itch","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2025-03-01","conditions":"Burn Scar, Itch Scarring, Wound","enrollment":44},{"nctId":"NCT01722812","phase":"PHASE2","title":"Cromoglicate in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01701843","phase":"PHASE2","title":"Cromoglicate in Mastocytosis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2012-10","conditions":"Mastocytosis","enrollment":7},{"nctId":"NCT03167216","phase":"EARLY_PHASE1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-08-01","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":20},{"nctId":"NCT05077917","phase":"PHASE3","title":"Cromolyn Sodium for Treatment of COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2021-11-15","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Pneumonia, Viral","enrollment":22},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT02664051","phase":"PHASE4","title":"Mast Cells in Acid-induced Intestinal Permeability","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-08","conditions":"Dyspepsia","enrollment":20},{"nctId":"NCT04846348","phase":"PHASE2","title":"Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis","status":"TERMINATED","sponsor":"Joseph Butterfield","startDate":"2021-07-26","conditions":"Cutaneous Mastocytoses","enrollment":1},{"nctId":"NCT02371941","phase":"PHASE4","title":"Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2014-12","conditions":"Eosinophilic Esophagitis","enrollment":16},{"nctId":"NCT04408664","phase":"PHASE3","title":"Influence of Cromones on Eucapnic Hyperventilation (EVH)-Test in Young (Elite) Athletes Who Tested Positive for EIB.","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-04-06","conditions":"Exercise-Induced Bronchoconstriction","enrollment":8},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT04570644","phase":"PHASE1","title":"Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2020-08-28","conditions":"Healthy Volunteers, Alzheimer Disease","enrollment":56},{"nctId":"NCT03202147","phase":"PHASE2","title":"Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)","status":"WITHDRAWN","sponsor":"AZTherapies, Inc.","startDate":"2023-12","conditions":"Ischemic Stroke, Post-stroke Cognitive Impairment","enrollment":""},{"nctId":"NCT00777348","phase":"PHASE2","title":"To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2007-11","conditions":"Asthma, Exercise-Induced","enrollment":62},{"nctId":"NCT00943397","phase":"PHASE3","title":"Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04","conditions":"Asthma","enrollment":190},{"nctId":"NCT02547818","phase":"PHASE3","title":"Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-09-15","conditions":"Alzheimer's Disease","enrollment":620},{"nctId":"NCT04428775","phase":"PHASE2","title":"A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease","status":"TERMINATED","sponsor":"AZTherapies, Inc.","startDate":"2020-09-08","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":"Indolent Systemic Mastocytosis","enrollment":135},{"nctId":"NCT01933464","phase":"PHASE1, PHASE2","title":"An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-08","conditions":"Papulopustular Rosacea","enrollment":10},{"nctId":"NCT01841307","phase":"PHASE1","title":"Cromolyn Detection of Silent Aspiration","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2015-07","conditions":"Gastroesophageal Reflux, Respiratory Aspiration, Idiopathic Pulmonary Fibrosis","enrollment":16},{"nctId":"NCT02566252","phase":"PHASE1","title":"Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)","status":"COMPLETED","sponsor":"Pulmotect, Inc.","startDate":"2015-07","conditions":"Healthy","enrollment":16},{"nctId":"NCT01346852","phase":"","title":"Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Asthma","enrollment":101437},{"nctId":"NCT02478957","phase":"PHASE2","title":"Treatment of Indolent Systemic Mastocytosis With PA101","status":"COMPLETED","sponsor":"Patara Pharma","startDate":"2015-06","conditions":"Mastocytosis, Systemic Mastocytosis, Indolent Systemic Mastocytosis","enrollment":41},{"nctId":"NCT02482324","phase":"PHASE1","title":"Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-06","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT01175525","phase":"PHASE3","title":"Treatment of Acute Stroke With Cromolyn(Single Dose)","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"","conditions":"Acute Stroke","enrollment":""},{"nctId":"NCT00745199","phase":"PHASE2","title":"Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2008-05","conditions":"End Stage Renal Disease, Pruritus","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Cromoglycate","genericName":"Cromoglycate","companyName":"Vishwajit Nimgaonkar, MD PhD","companyId":"vishwajit-nimgaonkar-md-phd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cromoglycate is a small molecule drug, classified as a mast cell stabilizer, which prevents the release of inflammatory chemicals such as histamine from mast cells. It has been studied in various clinical trials for conditions including pediatric asthma, rhinitis, and allergic reactions, as well as Alzheimer's disease and acute stroke.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-01-03T00:00:00.000Z","mah":"BLACKSMITH BRANDS","brand_name_local":"NASALCROM","application_number":"NDA020463"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}